Mr. Speaker, ALS patients in Canada suffer from a lack of access to new therapeutic treatments and a quarter of Canadian ALS patients do not have access to clinical trials within their own provinces. The current system is prohibitive to ALS patients who wish to access new therapies that could significantly improve their quality of life. We have a duty to care for those individuals who are vulnerable, and we must do better. We must work with our international partners to uncover and approve new treatments for ALS patients, ensure that ALS therapies are covered by provincial health authorities and make certain that ALS patients have equal access to the treatments they need. Pursuing these goals will see the burden of ALS decrease with patients living longer with less severe symptoms and a greater ability to contribute to society.
In the House of Commons on September 28th, 2020. See this statement in context.